Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Daniel LaBarbera

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-4116
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOP-Administration


    Collapse Research 
    Collapse research activities and funding
    R01CA251361     (LABARBERA, DANIEL VINCENT)Aug 1, 2020 - Apr 30, 2025
    NIH
    The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer.
    Role: Principal Investigator
    R01AI120365     (CHEN, CHAOPING)Sep 1, 2016 - Aug 31, 2020
    NIH
    Assay Development for Identification of HIV-1 Protease Autoprocessing Specific Inhibitors
    Role: Co-Principal Investigator
    R01EY021498     (PETRASH, JONATHAN MARK)Sep 30, 2011 - Aug 31, 2017
    NIH
    Novel Therapeutics Against Diabetic Eye Disease
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer. Biomed Pharmacother. 2024 Jan; 170:116037. PMID: 38128184.
      View in: PubMed
    2. Kellett T, Noor R, Zhou Q, Esquer H, Sala R, Stojanovic P, Rudolph J, Luger K, LaBarbera DV. HTS discovery of PARP1-HPF1 complex inhibitors in cancer. SLAS Discov. 2023 12; 28(8):394-401. PMID: 37844763.
      View in: PubMed
    3. Agarwal N, Zhou Q, Arya D, Rinaldetti S, Duex J, LaBarbera DV, Theodorescu D. AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer. Int J Mol Sci. 2022 Sep 16; 23(18). PMID: 36142729.
      View in: PubMed
    4. Rinaldetti S, Zhou Q, Abbott JM, de Jong FC, Esquer H, Costello JC, Theodorescu D, LaBarbera DV. High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes. Int J Mol Sci. 2022 Sep 14; 23(18). PMID: 36142576.
      View in: PubMed
    5. Prutton KM, Marentette JO, Leifheit BA, Esquer H, LaBarbera DV, Anderson CC, Maclean KN, Roede JR. Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21. Free Radic Biol Med. 2022 06; 186:32-42. PMID: 35537597.
      View in: PubMed
    6. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961. PMID: 35192363.
      View in: PubMed
    7. Agarwal N, Rinaldetti S, Cheikh BB, Zhou Q, Hass EP, Jones RT, Joshi M, LaBarbera DV, Knott SRV, Cech TR, Theodorescu D. TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer. Proc Natl Acad Sci U S A. 2021 09 21; 118(38). PMID: 34518220.
      View in: PubMed
    8. Esquer H, Zhou Q, Nemkov T, Abraham AD, Rinaldetti S, Chen YC, Zhang X, Orman MV, D'Alessandro A, Ferrer M, Messersmith WA, LaBarbera DV. Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. Oncogene. 2021 04; 40(16):2884-2897. PMID: 33742123.
      View in: PubMed
    9. Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212. PMID: 33595872.
      View in: PubMed
    10. Strand KA, Lu S, Mutryn MF, Li L, Zhou Q, Enyart BT, Jolly AJ, Dubner AM, Moulton KS, Nemenoff RA, Koch KA, LaBarbera DV, Weiser-Evans MCM. High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog): Central Role for PTEN in 5-Azacytidine Protection Against Pathological Vascular Remodeling. Arterioscler Thromb Vasc Biol. 2020 08; 40(8):1854-1869. PMID: 32580634.
      View in: PubMed
    11. Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612. PMID: 32499299.
      View in: PubMed
    12. Esquer H, Zhou Q, Abraham AD, LaBarbera DV. Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discov. 2020 08; 25(7):734-743. PMID: 32484006.
      View in: PubMed
    13. Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203. PMID: 31675229.
      View in: PubMed
    14. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048. PMID: 30733375.
      View in: PubMed
    15. Huang L, Li L, Tien C, LaBarbera DV, Chen C. Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment. Sci Rep. 2019 01 22; 9(1):301. PMID: 30670786.
      View in: PubMed
    16. Feibelman KM, Fuller BP, Li L, LaBarbera DV, Geiss BJ. Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme. Antiviral Res. 2018 06; 154:124-131. PMID: 29680670.
      View in: PubMed
    17. Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 07 01; 24(13):3059-3068. PMID: 29615459.
      View in: PubMed
    18. Kalita D, Holm DG, LaBarbera DV, Petrash JM, Jayanty SS. Inhibition of a-glucosidase, a-amylase, and aldose reductase by potato polyphenolic compounds. PLoS One. 2018; 13(1):e0191025. PMID: 29370193.
      View in: PubMed
    19. Bashyal B, Li L, Bains T, Debnath A, LaBarbera DV. Larrea tridentata: A novel source for anti-parasitic agents active against Entamoeba histolytica, Giardia lamblia and Naegleria fowleri. PLoS Negl Trop Dis. 2017 Aug; 11(8):e0005832. PMID: 28793307.
      View in: PubMed
    20. Fettig LM, McGinn O, Finlay-Schultz J, LaBarbera DV, Nordeen SK, Sartorius CA. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017 11 02; 36(44):6074-6084. PMID: 28692043.
      View in: PubMed
    21. Hoffman AF, Simpson KJ, Horvath P, Lovitt C, Silver S, Easton E, LaBarbera DV, Mendez M, Rothenberg ME, Seldin J, Wardwell-Swanson J, Fennell M. SBI2 HCS/HCA 3D Imaging: Best Practices and Unmet Needs Colloquium. Assay Drug Dev Technol. 2017 01; 15(1):1-7. PMID: 28092461.
      View in: PubMed
    22. Chang KC, Li L, Sanborn TM, Shieh B, Lenhart P, Ammar D, LaBarbera DV, Petrash JM. Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract. J Nat Prod. 2016 05 27; 79(5):1439-44. PMID: 27140653.
      View in: PubMed
    23. Zhou Q, Abraham AD, Li L, Babalmorad A, Bagby S, Arcaroli JJ, Hansen RJ, Valeriote FA, Gustafson DL, Schaack J, Messersmith WA, LaBarbera DV. Topoisomerase IIa mediates TCF-dependent epithelial-mesenchymal transition in colon cancer. Oncogene. 2016 09 22; 35(38):4990-9. PMID: 26947016.
      View in: PubMed
    24. Medellin DC, Zhou Q, Scott R, Hill RM, Frail SK, Dasari R, Ontiveros SJ, Pelly SC, van Otterlo WA, Betancourt T, Shuster CB, Hamel E, Bai R, LaBarbera DV, Rogelj S, Frolova LV, Kornienko A. Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities. J Med Chem. 2016 Jan 14; 59(1):480-5. PMID: 26641132.
      View in: PubMed
    25. Li L, Zhou Q, Voss TC, Quick KL, LaBarbera DV. High-throughput imaging: Focusing in on drug discovery in 3D. Methods. 2016 Mar 01; 96:97-102. PMID: 26608110.
      View in: PubMed
    26. Chang KC, Snow A, LaBarbera DV, Petrash JM. Aldose reductase inhibition alleviates hyperglycemic effects on human retinal pigment epithelial cells. Chem Biol Interact. 2015 Jun 05; 234:254-60. PMID: 25451566.
      View in: PubMed
    27. Li L, Abraham AD, Zhou Q, Ali H, O'Brien JV, Hamill BD, Arcaroli JJ, Messersmith WA, LaBarbera DV. An improved high yield total synthesis and cytotoxicity study of the marine alkaloid neoamphimedine: an ATP-competitive inhibitor of topoisomerase IIa and potent anticancer agent. Mar Drugs. 2014 Sep 19; 12(9):4833-50. PMID: 25244109.
      View in: PubMed
    28. Chang KC, Ponder J, Labarbera DV, Petrash JM. Aldose reductase inhibition prevents endotoxin-induced inflammatory responses in retinal microglia. Invest Ophthalmol Vis Sci. 2014 May 02; 55(5):2853-61. PMID: 24677107.
      View in: PubMed
    29. Reid BG, Jerjian T, Patel P, Zhou Q, Yoo BH, Kabos P, Sartorius CA, Labarbera DV. Live multicellular tumor spheroid models for high-content imaging and screening in cancer drug discovery. Curr Chem Genom Transl Med. 2014; 8(Suppl 1):27-35. PMID: 24596682.
      View in: PubMed
    30. Li L, Chang KC, Zhou Y, Shieh B, Ponder J, Abraham AD, Ali H, Snow A, Petrash JM, LaBarbera DV. Design of an amide N-glycoside derivative of ?-glucogallin: a stable, potent, and specific inhibitor of aldose reductase. J Med Chem. 2014 Jan 09; 57(1):71-7. PMID: 24341381.
      View in: PubMed
    31. LaBarbera DV, Skibo EB. The synthesis of vinylogous amidine heterocycles. J Org Chem. 2013 Dec 06; 78(23):11887-95. PMID: 24228868.
      View in: PubMed
    32. Chang KC, Laffin B, Ponder J, Enzs?ly A, N?meth J, LaBarbera DV, Petrash JM. Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of aldose reductase in murine macrophages and ocular tissues. Chem Biol Interact. 2013 Feb 25; 202(1-3):283-7. PMID: 23247009.
      View in: PubMed
    33. Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer. 2013 Feb; 4(1):36-49. PMID: 23184698.
      View in: PubMed
    34. LaBarbera DV, Reid BG, Yoo BH. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Discov. 2012 Sep; 7(9):819-30. PMID: 22788761.
      View in: PubMed
    35. Yoo BH, Axlund SD, Kabos P, Reid BG, Schaack J, Sartorius CA, LaBarbera DV. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer. J Biomol Screen. 2012 Oct; 17(9):1211-20. PMID: 22751729.
      View in: PubMed
    36. Puppala M, Ponder J, Suryanarayana P, Reddy GB, Petrash JM, LaBarbera DV. The isolation and characterization of ?-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis. PLoS One. 2012; 7(4):e31399. PMID: 22485126.
      View in: PubMed
    37. Ponder J, Yoo BH, Abraham AD, Li Q, Ashley AK, Amerin CL, Zhou Q, Reid BG, Reigan P, Hromas R, Nickoloff JA, LaBarbera DV. Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIa activity through ATP-competitive inhibition. Mar Drugs. 2011; 9(11):2397-2408. PMID: 22163192.
      View in: PubMed
    38. Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, Schaack J, LaBarbera DV. 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen. 2011 Feb; 16(2):141-54. PMID: 21297102.
      View in: PubMed
    39. LaBarbera DV, Modzelewska K, Glazar AI, Gray PD, Kaur M, Liu T, Grossman D, Harper MK, Kuwada SK, Moghal N, Ireland CM. The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs. 2009 Jul; 20(6):425-36. PMID: 19369860.
      View in: PubMed
    40. Hargreaves RH, David CL, Whitesell LJ, Labarbera DV, Jamil A, Chapuis JC, Skibo EB. Discovery of quinolinediones exhibiting a heat shock response and angiogenesis inhibition. J Med Chem. 2008 Apr 24; 51(8):2492-501. PMID: 18363347.
      View in: PubMed
    41. LaBarbera DV, Bugni TS, Ireland CM. The total synthesis of neoamphimedine. J Org Chem. 2007 Oct 26; 72(22):8501-5. PMID: 17900144.
      View in: PubMed
    42. Hoang H, LaBarbera DV, Mohammed KA, Ireland CM, Skibo EB. Synthesis and biological evaluation of imidazoquinoxalinones, imidazole analogues of pyrroloiminoquinone marine natural products. J Med Chem. 2007 Sep 20; 50(19):4561-71. PMID: 17705462.
      View in: PubMed
    43. Laird DW, LaBarbera DV, Feng X, Bugni TS, Harper MK, Ireland CM. Halogenated cyclic peptides isolated from the sponge Corticium sp. J Nat Prod. 2007 May; 70(5):741-6. PMID: 17391049.
      View in: PubMed
    44. Lira SP, Vita-Marques AM, Seleghim MH, Bugni TS, LaBarbera DV, Sette LD, Sponchiado SR, Ireland CM, Berlinck RG. New destruxins from the marine-derived fungus Beauveria felina. J Antibiot (Tokyo). 2006 Sep; 59(9):553-63. PMID: 17136888.
      View in: PubMed
    45. LaBarbera DV, Skibo EB. Solution kinetics of CC-1065 A-ring opening: substituent effects and general acid/base catalysis. J Am Chem Soc. 2006 Mar 22; 128(11):3722-7. PMID: 16536546.
      View in: PubMed
    46. Labarbera DV, Skibo EB. Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products. Bioorg Med Chem. 2005 Jan 17; 13(2):387-95. PMID: 15598560.
      View in: PubMed
    LaBarbera's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (292) concept(s)
    _
    Co-Authors Expand Description
    See all (29) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)